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Results: Of the 89 patients enrolled, 84 were assessable for efﬁcacy 
and toxicity: 41 patients (median age 65 years, male/female 30/11, 
stage IIIB/IV 7/34) in the CP arm and 43 (median age 67 years, 
male/female 31/12, stage IIIB/IV 7/36) in the GV arm. The 1-year 
survival rates and the median survival time were 22.0% (95% CI, 9.3 
to 34.6%) and 5.9 months for the CP arm, and 27.9% (95% CI, 14.5 
to 41.3%) and 6.0 months for the GV arm, respectively. On the other 
hand, the overall response rate and the time to progression were 29.3% 
(95% CI, 16.1 to 45.5%) and 2.9 months for the CP and 20.9% (95% 
CI, 9.3 to 34.6%) and 2.6 months for the GV arm, respectively. The 
selected grade 3/4 toxicity in the CP and GV arms included neutropenia 
(67.5% vs 65.1%, respectively), anemia (12.5% vs 30.2%), throm-
bocytopenia (7.5% vs 11.6%), febrile neutropenia (17.1% vs 11.6%), 
pneumonitis (4.9% vs 11.6%), liver dysfunction (2.5% vs 9.3%), and 
neuropathy (4.9% vs 0%). One treatment-related death occurred in the 
CP compared with three in the GV arm.The QOL improved after each 
treatment and it was similar between the two arms.
Conclusions: Both CP and GV arms appear to be active in PS 2 
patients with advanced NSCLC with 1-year survival rates of more than 
20% and median survival times of approximately 6 months. Although 
the toxicity proﬁles were different between the two arms, the GV arm 
caused more treatment-related deaths.
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Backgrounds: There are only a few reports about third and fourth line 
chemotherapy for advanced non-small cell lung cancer (NSCLC). The 
efﬁcacy of salvage chemotherapy has not been demonstrated yet. We 
conducted a retrospective study to investigate the efﬁcacy of third and 
fourth line chemotherapy.
Patients and Methods: This study was retrospective study of salvage 
chemotherapy. Patients diagnosed with advanced NSCLC or recurred 
after the curative resection in Kanazawa University Hospital and 
received more than one regimen chemotherapy were enrolled to this 
study. Patients received adjuvant chemotherapy after the curative resec-
tion was excluded. Response was evaluated using RECIST guidelines. 
Survival was estimated by the Kaplan-Meier method.
Results: Consecutive 82 patients were treated from January 2002 to 
March 2005. Median age of all patients was 62 (33-88), male was 51 
and female was 31. Histology included adenocarcinoma 62 (76%), 
squamous cell carcinoma 12 (14%), large cell carcinoma 4 (5%), and 
other 4 (5%). Response rate of ﬁrst line chemotherapy was 19.2% (15 
of 82). Overall survival of 82 patients was 352 days. 36 of 82 patients 
(44%) received more than three regimens of chemotherapy. Median age 
of 36 patients was 60 year old (40-81), male/female; 23/13. Histologi-
cal subtype were adenocarcinoma 32 (76%), squamous cell carcinoma 
5 (12%), large cell carcinoma 3 (7%), and other 2 (5%). Performance 
status 0-1 was 30 (83.3%). Most of chemotherapy from third line was 
geﬁtinib or single agent of third generation chemotherapeutic drug, and 
platinum based regimens were administered in 3 cases in third line and 
2 cases in fourth line. Response rate in third and fourth line chemother-
apy were 13.8% (4 of 36, geﬁtinib in 3 cases and irinotecan in 1case) 
and 14.3% (2 of 16, geﬁtnib + paclitaxel and cisplatin + gemcitabne), 
respectively. There is no objective response by ﬁﬁth chemotherapy 
regimen. Median survival from third line chemotherapy was 204 days.
Conclusions: Response rate in third and fourth line chemotherapy 
was more than 10%. Prospective study to prove the efﬁcacy of salvage 
chemotherapy is needed because of lack of evidence for salvage che-
motherapy.
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Background: Platinum-based doublet chemotherapy is generally 
accepted as standard therapy in advanced NSCLC patients. However, 
symptomatic beneﬁt under the serial chemotherapy is rarely evaluated 
in the phase II settings. The objectives of this study were to evaluate ef-
ﬁcacy, toxicity, and quality-of-life (QOL) status in such patients treated 
with CV.
Methods: Pathologically proven advanced NSCLC patients of age un-
der 70 with good performance status (PS) were eligible. The treatment 
consisted of carboplatin (AUC = 5.0) as a 1-hour infusion on day 1, and 
vinorelbine (25 mg/m2) as a 10-minute infusion on days 1 and 8, re-
peated every 21 days, according to the results of our phase I study. The 
Response Evaluation Criteria In Solid Tumor guideline was used for 
assessing efﬁcacy, Commom Terminology Critera for Adverse Events 
v3.0 for toxicity, and EORTC QLQ-C30 / LC13 for QOL.
Results: Thirty-ﬁve patients with mean age of 59.5 years were en-
rolled. Twenty-ﬁve were male, and 10 were female. Thirty-one patients 
were stage IV disease, and 29 / 5 / 1 patients had adenocarcinoma / 
squamous cell carcinoma / adenosquamous cell carcinoma, respective-
ly. Total number of delivered courses was 116, with an average of 3.3 
courses per patient. Treatment schedule was delayed in 29 courses, and 
the treatment dose was reduced in 9 courses. Overall response rate was 
37.1% with 13 partial-response patients. Median survival time was 391 
days, and median duration of response was 118 days. Grade 3 / 4 leuko-
penia, neutropenia, and anemia were observed in 19 / 7, 7 / 24, and 8 / 
0 patients. Two grade 3 febrile neutropenia patients were also reported. 
QLQ-C30 results showed almost no difference from the baseline in 
global health status / QOL and functional scales after treatment, but 
signiﬁcant pain reduction and dyspnea worsening in symptom scales / 
items. QLQ-LC13 also resulted in signiﬁcant reduction of cough, pain, 
and dysphagia, with signiﬁcant worsening of hair loss and dyspnea. 
Worsening of dyspnea seemed to be associated with anemia progres-
sion during the treatment.
Conclusions: The CV combination is well tolerated with comparable 
activity in advanced NSCLC patients, and QOL assessment revealed 
symptomatic efﬁcacy of this treatment. Because of the low non-hema-
tological toxicity proﬁle, this combination may be suitable for treating 
elderly and / or unﬁt patients. In this regard, we are now on the investi-
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gation of this regimen for unﬁt patients, with reduced vinorelbine dose 
of 20 mg/m2 aiming at lower hematological toxicity.
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Background: Single-agent chemotherapy (gemcitabine or vinorel-
bine) is currently the standard treatment for elderly advanced NSCLC 
patients. The combination of gemcitabine+docetaxel was active but not 
well tolerated in this subset (Hainsworth et al, Clin Lung Cancer 2003). 
Modiﬁed schedule of docetaxel (37.5 mg/m2 on day 1 and 8 every 3 
weeks) is active and well tolerated in pre-treated elderly advanced 
NSCLC patients (Tibaldi et al, Clin Lung Cancer, 2006). Aim of this 
study was to evaluate the activity and the toxicity of a sequential regi-
men of gemcitabine followed by docetaxel in elderly advanced NSCLC 
patients.
Methods: Chemo-naïve elderly patients (> 70 years old) with histolog-
ically or cytologically conﬁrmed stage IIIB (positive pleural effusion or 
metastatic supraclavear lymph nodes) or IV NSCLC and a performance 
status (PS) 0-2 were treated with gemcitabine 1200 mg/m2 on Day 1 
and 8 every 3 weeks for 3 cycles followed by, in case of no progres-
sive disease, docetaxel 37.5 mg/m2 on Day 1 and 8 every 3 weeks for 
further 3 cycles. 
Results: Fifty-six patients were enrolled into the study: 46 male and 10 
women; 13 stage IIIB and 43 stage IV; 7 PS 0, 38 PS1, 11 PS2; median 
age was 75 years (range 70-84). The median number of major comor-
bidities was 2.
All the patients were evaluable for toxicity and 45 were evaluable for 
response. Toxicity was mild; afebrile grade 3-4 neutropenia was ob-
served in 4 patients (7.1%) and grade 3 thrombocytopenia in 2 patients 
(3.6%); no grade 3-4 anaemia was observed. Non-haematological grade 
3-4 toxicities were: fatigue in 5 patients (8.9%), diarrhoea in 1 patient 
(1.8%) and mucositis in 2 patients (3.6%). Nine of the 45 evaluable pa-
tients showed a partial response (20%, 95% CI 9.6% - 34.6%), 17 had a 
stable disease (37.8%) and 19 a progression (42.2%). Five patients had 
a conversion from stable disease to partial response by docetaxel. 
Conclusion: Sequential chemotherapy with gemcitabine and docetaxel 
seems active and well tolerated in elderly advanced NSCLC patients. 
The ﬁnal analysis will be presented at the meeting.
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Objectives: The aim of the present study is to evaluate the efﬁcacy and 
toxicity of weekly docetaxel combined with cisplatin as ﬁrst-line che-
motherapy in patients with locally advanced or metastatic NSCLC and 
to identify the optimal dose of weekly docetaxel to be administered.
Methods: Chemonaive patients over 18 years of age with NSCLC 
stage IIIB and malignant pleural effusion, or stage IV were enrolled in 
this study. In the dose ﬁnding portion, patients received docetaxel once 
weekly at an initial dose of 25 mg/m2 for three weeks with cisplatin 
added on day 15 at a ﬁxed dose of 75 mg/m2. The dose of docetaxel 
was escalated by 3 mg/m2 for each level to a maximum dose of 34 
mg/m2. Treatment was repeated every 4 weeks for 6 cycles unless 
progressive disease, unacceptable toxicity, or consent withdrawal were 
present. Patients were enrolled in cohorts of 3 to receive combination 
chemotherapy. If a dose-limiting toxicity (DLT) occurred in 1 of the 
3 patients, 3 additional patients would be enrolled at that dose level. 
DLT was deﬁned as any grade 3-4 non-hematological toxicity (except 
alopecia, nausea and vomiting), grade 4 hematologic toxicity, or grade 
3 hematologic toxicity with complications (e.g. neutropenic fever or 
bleeding). The maximum-tolerated dose (MTD) was deﬁned as the 
dose immediately below the level associated with the occurrence of 
DLT in more than one-third of treated patients. 
Results: Forty-nine patients were enrolled into this phase I/II study. In 
the dose-ﬁnding portion, the MTD of docetaxel was not reached since 
no patient developed DLT when docetaxel was given at the highest 
dose of 34 mg/m2. In the phase II portion, 18 patients received docetax-
el at 34 mg/m2 and 14 patients received 31 mg/m2. Of the 49 eligible 
patients, none had a complete response and 19 achieved a partial 
response. The overall response rate was 38.8% (95% CI: 26.7-55.6%). 
Twenty-one patients (42.9%) had stable disease. The median survival 
was 13.1 months (95% CI: 10.4 - 15.6 months). Only 2 patients (4.1%) 
developed grade 3/4 neutropenia and there was no febrile neutropenia. 
The major non-hematological toxicities were asthenia and peripheral 
neuropathy, but most of them were grade 1 or 2.
Conclusions: Weekly docetaxel combined with cisplatin on day 15 has 
an acceptable toxicity proﬁle and is an effective regimen as ﬁrst-line 
chemotherapy in NSCLC. No dose-limiting toxicities were observed 
even when weekly docetaxel was given at 34 mg/m2.
